• Explore /
  • Poster
  • / Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301.

Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301.

Abstract Video & Slides Poster

Authors

null

Luis Manso

Hospital Universitario 12 de Octubre and GEICO, Madrid, Spain

Luis Manso , Ignace Vergote , Keiichi Fujiwara , Antoine Angelergues , Michal Zikan , Scott Jordan , Jung-Yun Lee , Lisa Barraclough , Fernando Cotait Maluf , Domenica Lorusso , Kan Yonemori , Christine Gennigens , Antonio Gonzalez Martin , Florian Heitz , Anneke M. Westermann , Allan Covens , Elizabeth Whalley , Yiyi Chen , Ibrahima Soumaoro , Leslie M. Randall

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Cervical Cancer

Clinical Trial Registration Number

NCT04697628

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 5531)

DOI

10.1200/JCO.2024.42.16_suppl.5531

Abstract #

5531

Poster Bd #

402

Abstract Disclosures

Similar Posters

First Author: Ignace Vergote

First Author: Krishnansu Sujata Tewari

Poster

2015 ASCO Annual Meeting

Outcomes with chemotherapies and molecular characteristics of <i>HER2</i>-mutant lung cancers.

Outcomes with chemotherapies and molecular characteristics of HER2-mutant lung cancers.

First Author: Juliana Eng

First Author: Rachel N. Grisham